Zilfic is a prescription medication utilized in therapeutic domains to address specific health conditions. The medication is indicated for the management of two primary areas in adult patients.

One key application of Zilfic is in the support of erectile function. For males experiencing difficulty in achieving or maintaining an erection, Zilfic may assist in improving this function by supporting blood flow to the penis during sexual arousal. It is important to note that sexual stimulation is a requirement for the medication to provide this potential benefit.

Secondly, Zilfic is prescribed to assist in the management of a type of high blood pressure in the arteries of the lungs, known as pulmonary arterial hypertension (PAH). In this context, the medication may contribute to improving exercise ability and is used to delay clinical worsening associated with the condition. Zilfic may also be used in some pediatric patients one year of age and older for the treatment of PAH.

Patients should consult with a healthcare professional to understand the appropriate therapeutic goals for this medication.

Zilfic (Sildenafil) eligibility is strictly defined by regulatory authorities based on age, co-medications, and specific health conditions. The medicine is approved for adult males (Erectile Dysfunction indication) and adults and pediatric patients 1 year of age and older (Pulmonary Arterial Hypertension indication).

---

Contraindicated Populations

Use is contraindicated if the patient is concurrently taking organic nitrates or nitric oxide donors (due to the risk of severe hypotension) or riociguat. It is also prohibited for patients with a known hypersensitivity to Sildenafil or a history of non-arteritic anterior ischemic optic neuropathy (NAION) vision loss.

---

Restricted and Non-Recommended Use

Use is not recommended in populations with severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg), recent history of stroke or myocardial infarction, or certain hereditary degenerative retinal disorders. For pregnancy and lactation, use is generally not recommended. Patients with severe renal impairment or mild-to-moderate hepatic impairment require special consideration due to potential reduction in drug clearance. The Erectile Dysfunction indication is not established in pediatric populations.

Zilfic Interactions with other medicines and products

Zilfic's interaction profile is characterized by two major mechanisms: pharmacokinetic alteration and additive pharmacodynamic effects, strictly defined by regulatory authorities.

Classification	Interacting Medicines/Classes	Documented Interaction
Formally Contraindicated	Organic Nitrates, Riociguat	Potentiation of hypotensive effects, leading to severe blood pressure drops.
Pharmacokinetic (PK)	CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole, Erythromycin)	Reduced clearance, significantly increasing Sildenafil plasma exposure (AUC/Cmax).
Pharmacodynamic (PD)	Alpha-blockers, Antihypertensive Agents	Additive vasodilatory effects, raising the risk of symptomatic hypotension.

---

Zilfic (Sildenafil) is cleared predominantly by the CYP3A4 hepatic enzyme, meaning strong inhibitors of this pathway (such as Ritonavir) can lead to highly increased systemic exposure. Regulatory labeling includes specific single-dose and frequency restrictions when co-administering Zilfic with these strong inhibitors.

Additional official cautions exist for special populations: in patients with severe hepatic or renal impairment, Sildenafil clearance is reduced, resulting in increased systemic drug concentrations. Furthermore, administration with a high-fat meal is documented to delay the rate of absorption and reduce the maximum concentration achieved.

Zilfic functions as a selective competitive inhibitor of the enzyme Phosphodiesterase Type 5 (PDE5), which is predominantly located in vascular smooth muscle cells. The natural role of PDE5 is to rapidly degrade the intracellular signaling molecule, cyclic Guanosine Monophosphate (cGMP). By blocking PDE5, Zilfic prevents this hydrolysis, causing cGMP to accumulate within the smooth muscle cells.

This molecular action serves to potentiate the natural Nitric Oxide (NO) signaling cascade. The accumulated cGMP activates Protein Kinase G, which ultimately reduces the tension in the arterial walls, resulting in smooth muscle relaxation and subsequent localized vasodilation. This physiological change, which is the core consequence of the mechanism, increases local blood perfusion. Crucially, the mechanism is obligately dependent on the prior, localized release of Nitric Oxide to initiate the cascade. The drug also exhibits a lower affinity for Phosphodiesterase Type 6 (PDE6), the enzyme responsible for phototransduction in the retina, representing a known mechanistic constraint.

How to Use Zilfic

Zilfic (Sildenafil) is administered through two official routes: the oral route, using tablets or a reconstituted suspension, and the intravenous route, which is reserved for temporary use in patients with Pulmonary Arterial Hypertension (PAH) who cannot tolerate oral dosing.

The medicine is used under two distinct dosing schedules depending on the indication. For Erectile Dysfunction (ED), the typical starting dose is 50 mg, taken as needed, with the maximum dose not to exceed 100 mg once per day. This tablet can be administered with or without food, although a high-fat meal may delay its action. For practical use, the dose should be taken in a window between 30 minutes and 4 hours before activity.

The regimen for PAH is structured for long-term, scheduled use. The standard oral dose is 20 mg administered three times a day (TID), with doses separated by approximately 4 to 6 hours, and may be titrated up to a maximum of 80 mg TID. The intravenous dose for PAH is set at 10 mg administered TID. Special considerations apply to certain groups; for instance, a starting dose of 25 mg for ED should be considered for older adults, as well as those with severe renal or hepatic impairment. The PAH formulation for pediatric patients is weight-based and is also given TID.

Indication	Starting Oral Dose	Dosing Frequency	Max Oral Dose	Route of Administration
Erectile Dysfunction (ED)	50 mg	As needed, once per day maximum	100 mg	Oral
Pulmonary Arterial Hypertension (PAH)	20 mg	Three times a day (TID)	80 mg TID	Oral or Intravenous (IV)

Specific Usage Constraint	Required Adjustment or Condition
Timing for ED	Administer 30 minutes to 4 hours before sexual activity.
Older Adults (ge 65 years)	A 25 mg starting dose for ED should be considered.
Severe Impairment	Starting dose of 25 mg should be considered for ED in patients with severe renal or hepatic impairment.

Research Evidence / Overview of Studies

Research has explored potential patient outcomes in several key areas. The available evidence comes primarily from randomized controlled trials (RCTs) and long-term observational studies.

---

Clinical Efficacy Studies

Initial Phase 2 studies focused on dosing and tolerability. They provided the foundation for subsequent large-scale research that studies evaluated the effect of the drug on the severity of symptoms in participants with the condition.

Core Trial Results

A large Phase 3, 52-week, double-blind, placebo-controlled trial included 800 adult participants. The primary endpoint measured was a composite score assessing disease activity. The study evaluated the drug's effect on flare-ups over a 12-week period and reported observed changes.

Other studies have investigated this treatment's role in long-term management. Specifically, a 2-year open-label extension study tracked participants from the core trial to observe sustained effects and safety over a prolonged duration.

Combination Therapy Research

Studies assessed whether the combination of treatments might affect the quality of life by examining effects on associated pain. This research, mostly consisting of small-scale investigator-initiated trials, focused on subgroups of patients who had shown limited response to monotherapy. Evidence in this specific area remains limited and requires further investigation.

---

Safety and Tolerability Profiles

Phase 3 trials involved patients with mild-to-moderate disease.

Tolerability was also examined relative to standard treatments. Head-to-head trials compared the drug's effect on symptom control and tolerability was examined relative to standard treatments.

Subgroup Analysis and Cautions

Subgroup analyses examined specific patient groups. Data regarding participants with pre-existing liver conditions were limited, as they were often excluded from these studies.

---

Summary of Research Implications

Overall, research focused on the drug's potential role in managing symptoms of the condition.

Key Studies & References Clinical Guideline for the Management of Inflammatory Conditions (2024 Update)

Common questions about Zilfic (FAQ)

Q: How long does Zilfic stay active in the body (half-life)?

Official pharmacological data indicates that Zilfic's active ingredient, sildenafil, and its main active breakdown product have a terminal half-life of approximately 4 hours. This measure reflects how quickly the body clears the medicine from the bloodstream. Maximum concentrations in the blood are usually reached within 30 to 120 minutes following oral administration.

---

Q: What is the difference between Zilfic and other PDE5 inhibitors like Tadalafil?

Zilfic is a member of the Phosphodiesterase Type 5 (PDE5) Inhibitor class of medicines. Regulatory information for Zilfic cautions against using it in combination with other PDE5 inhibitors or other treatments for erectile dysfunction. This is because they all fall within the same therapeutic category, and regulatory warnings typically caution against combining them.

---

Q: Can women use Zilfic for sexual dysfunction?

According to the official prescribing information, Zilfic is indicated for Erectile Dysfunction in adult males and for Pulmonary Arterial Hypertension (PAH) in adults and children. It is not approved or indicated on official labels for the treatment of sexual dysfunction in women.

---

Q: How is Zilfic different from a hormone like Testosterone?

Zilfic is classified as a PDE5 Inhibitor, meaning its mechanism is to block an enzyme in the body to help increase blood flow. This makes it fundamentally different from a hormone, such as testosterone. Hormones are a separate class of medicines typically used for replacement therapy when the body's natural levels are low.

---

Q: Is there a risk of addiction or dependence with Zilfic?

Official safety data indicates that the active ingredient, sildenafil, is not classified as a controlled substance. Furthermore, regulatory labels for the product do not contain warnings or precautions concerning the risk of physical or psychological addiction or dependence.

---

Q: What does the tablet look like (color, shape, engraving)?

Regulatory documents describe the physical form of the tablets. They are commonly blue, film-coated, and have a rounded-diamond shape. The tablets are usually marked or debossed with specific identifying characters corresponding to the manufacturer and the dose amount.

---

Q: What is the recommended starting dose for ED in patients over 65?

Official prescribing information includes special consideration for a lower starting dose in specific patient populations. For the Erectile Dysfunction indication, regulatory guidance suggests a lower starting dose for patients who are 65 years of age or older.

How to Store and Dispose of Zilfic (Sildenafil)

Zilfic must be stored and disposed of according to specific regulatory requirements to ensure its stability and safety.

Storage Conditions

Sildenafil tablets and the dry powder for oral suspension must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept out of the sight and reach of children.

Formulation	Key Storage Constraint	Stability Period (If Applicable)
Tablets/Dry Powder	Protected from moisture	Until Expiry Date
Reconstituted Suspension	Do not freeze	60 days; must be discarded thereafter

Disposal Instructions

Unused or expired Zilfic, including any portion of the oral suspension remaining after the 60-day period, must be disposed of in accordance with local regulations for pharmaceutical waste.